Predictive Oncology (NASDAQ:POAI) Shares Pass Below 200 Day Moving Average of $0.66

Predictive Oncology Inc. (NASDAQ:POAI – Get Rating) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.66 and traded as low as $0.42. Predictive Oncology shares last traded at $0.44, with a volume of 238,105 shares trading hands.

Predictive Oncology Stock Performance

The stock’s 50-day moving average is $0.41 and its 200 day moving average is $0.66. The firm has a market cap of $29.11 million, a P/E ratio of -1.42 and a beta of 1.35.

Predictive Oncology (NASDAQ:POAI – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The medical instruments supplier reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Predictive Oncology had a negative net margin of 1,314.56% and a negative return on equity of 27.33%. The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.00 million. On average, research analysts anticipate that Predictive Oncology Inc. will post -0.06 EPS for the current year.

Insider Activity at Predictive Oncology

In other news, Director Charles Lee Sr Nuzum, Sr. bought 200,000 shares of the stock in a transaction on Friday, May 20th. The stock was purchased at an average price of $0.31 per share, for a total transaction of $62,000.00. Following the acquisition, the director now owns 286,164 shares in the company, valued at $88,710.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director J Melville Engle bought 159,500 shares of the stock in a transaction on Tuesday, May 24th. The stock was purchased at an average price of $0.37 per share, for a total transaction of $59,015.00. Following the acquisition, the director now owns 203,393 shares in the company, valued at $75,255.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Charles Lee Sr Nuzum, Sr. bought 200,000 shares of the stock in a transaction on Friday, May 20th. The shares were purchased at an average price of $0.31 per share, with a total value of $62,000.00. Following the acquisition, the director now owns 286,164 shares in the company, valued at approximately $88,710.84. The disclosure for this purchase can be found here. Insiders bought a total of 378,175 shares of company stock worth $126,796 in the last quarter. Corporate insiders own 0.76% of the company’s stock.

Hedge Funds Weigh In On Predictive Oncology

Several hedge funds have recently modified their holdings of POAI. Charles Schwab Investment Management Inc. bought a new position in shares of Predictive Oncology in the 1st quarter valued at about $54,000. RB Capital Management LLC bought a new position in shares of Predictive Oncology in the 2nd quarter valued at about $65,000. Finally, Virtu Financial LLC bought a new position in shares of Predictive Oncology in the 1st quarter valued at about $66,000. Institutional investors own 6.23% of the company’s stock.

Predictive Oncology Company Profile

(Get Rating)

Predictive Oncology Inc, a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation.